



Memo Therapeutics AG announces completion of a first commercial project validating its proprietary MemoMAB™ antibody technology platform.

Basel/Zurich, Switzerland, Nov 22, 2016, Memo Therapeutics AG, a privately-held therapeutic antibody company today announced the completion of a first commercial project using its proprietary MemoMAB™ antibody discovery platform.

The project's objective was to discover monoclonal antibodies against a short extracellular domain (ECD) of a cancer target as candidates for the development of a therapeutic antibody construct. Due to the requirements of the project, rabbits were chosen as host animals and MemoMAB™ delivered a portfolio of specific antibodies fulfilling the client's quality criteria within 6 weeks.

"We were impressed by the way Memo Therapeutics handled this project", commented the client's CSO. "The company was able to hand over a number of antibody candidates less than 2 months after obtaining the immunized rabbits, with the molecules having undergone a thorough selection process including a complex 3-step screening program. We look forward to further characterizing these promising candidate antibodies. Based on this excellent experience, their MemoMAB™ technology is a very probable candidate technology for our future discovery programs."

MEMO's CSO Christoph Esslinger commented: "This was a unique opportunity for MEMO to show the power of the MemoMAB™ technology. We are delighted that the technology delivered on its promises in a first commercial project."

About MemoMAB™

MemoMAB™ is a single cell-based technology platform and the only technology to date that enables banking and expression screening of large authentic antibody repertoires (antibodyomes) of human and animal origin. It uses state of the art high throughput single cell technology for the rapid/fast processing of millions of antibody producing cells.

MemoMAB™ opens up new opportunities in the fields of Immune repertoire analysis, antibody- and target discovery:

- Rapid banking of complete authentic antibody repertoires of human or animal donors
- Unmatched repertoire analysis by single-cell based expression screening
- Unmatched efficiency resulting in more antibodies to choose from



About Memo Therapeutics AG:

Memo Therapeutics AG, a Spin Off of the Swiss Federal Institute of Technology (ETHZ) is an innovator in the field of antibody discovery and immune repertoire analysis. MEMO is a preclinical startup and focuses on proprietary lead generation programs and collaborations with the biotech/pharma industry.



Media contact:

Dr. Armin W. Mäder, CEO

media@memo-therapeutics.com

www.memo-therapeutics.com

Memo Therapeutics AG, c/o BPL D-BSSE ETH, Mattenstrasse 26, 4058 Basel, Switzerland.